Does CANAKINUMAB Cause Concomitant disease aggravated? 56 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 56 reports of Concomitant disease aggravated have been filed in association with CANAKINUMAB (Ilaris). This represents 0.5% of all adverse event reports for CANAKINUMAB.
56
Reports of Concomitant disease aggravated with CANAKINUMAB
0.5%
of all CANAKINUMAB reports
4
Deaths
32
Hospitalizations
How Dangerous Is Concomitant disease aggravated From CANAKINUMAB?
Of the 56 reports, 4 (7.1%) resulted in death, 32 (57.1%) required hospitalization, and 4 (7.1%) were considered life-threatening.
Is Concomitant disease aggravated Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CANAKINUMAB. However, 56 reports have been filed with the FAERS database.
What Other Side Effects Does CANAKINUMAB Cause?
Pyrexia (1,327)
Inappropriate schedule of drug administration (1,238)
Drug ineffective (1,078)
Inappropriate schedule of product administration (944)
Pain (858)
Condition aggravated (771)
Malaise (684)
Off label use (557)
Arthralgia (555)
Rash (505)
What Other Drugs Cause Concomitant disease aggravated?
SACUBITRIL\VALSARTAN (533)
SECUKINUMAB (461)
FINGOLIMOD (425)
MACITENTAN (286)
OMALIZUMAB (186)
SELEXIPAG (166)
METHOTREXATE (150)
RUXOLITINIB (142)
OCTREOTIDE (125)
BOSENTAN (123)
Which CANAKINUMAB Alternatives Have Lower Concomitant disease aggravated Risk?
CANAKINUMAB vs CANDESARTAN
CANAKINUMAB vs CANDESARTAN CILEXETIL
CANAKINUMAB vs CANDESARTAN CILEXETIL\HYDROCHLOROTHIAZIDE
CANAKINUMAB vs CANGRELOR
CANAKINUMAB vs CANIS LUPUS FAMILIARIS SKIN